ArticleLifetime data analysis2026
Optimal designs for discrete-time survival models with competing risks.
Article in Lifetime data analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Current methodological research on randomized controlled trial design has predominantly focused on studies with a single primary endpoint. However, many trials in practice involve multiple competing target events. The optimal designs for survival trials with competing target events have not been systematically addressed in the statistical literature. This paper fills this significant gap by developing design methodologies for randomized discrete-time-to-event trials with competing endpoints. We derive the Fisher information matrix for the general discrete-time survival model (DTSM) by transforming the original discrete-time survival data into proper multinomial responses. By introducing a cost-based generalized [Formula: see text]-optimal design criterion, we identify various types of optimal designs for estimating the treatment effects. Under the assumption of a parametric competing risks model for the underlying survival process, we demonstrate that the optimal treatment allocation scheme is critically influenced by the parameter values within this model. Our methodology is applied to the redesign of the SANAD trial, which examines withdrawal times from anti-epileptic drugs, thereby highlighting the advantages of our optimal design strategies. A key finding is that assigning subjects equally to the different groups in a two-arm DTSM trial with competing risks is generally a favorable choice, unless the hazard rates over the duration of the trial in both groups are low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.